The global monoclonal antibodies market size is expected to grow from $168.70 billion in 2021 to $188.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs market is expected to reach $292.22 billion in 2026 at a CAGR of 11.6%.
What is the Global Monoclonal Antibodies (MAbs) Market?
The monoclonal antibodies (MAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies, and other MAbs for human beings and animals.
Get a Sample of the global monoclonal antibodies (MAbs) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&&type=smp
What drives the Global Monoclonal Antibodies (MAbs) Market?
The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.
Get the full global monoclonal antibodies (MAbs) industry report here:
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Global Monoclonal Antibodies (MAbs) Market Segments
The global monoclonal antibodies (MAbs) market is segmented:
By Source: Murine, Chimeric, Humanized, Human
By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular and Cerebrovascular, Others
By End-User: Hospitals, Private Clinics, Research Institutes
By Geography: The regions covered in the monoclonal antibodies (MAbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Monoclonal Antibodies (MAbs) Global Market Report 2022provides market size and growth forecasts for the global monoclonal antibodies (MAbs) market, global monoclonal antibodies (MAbs) market share, monoclonal antibodies (MAbs) market segments and geographies, monoclonal antibodies (MAbs) market competitive landscape including leading competitors’ revenues, profiles and market shares. The monoclonal antibodies (MAbs) market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Monoclonal Antibodies (MAbs) Industry Playersinclude Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc., Norvatis AG, Pfizer Inc, Thermofischer Scientific, Elililly and Company and Bristol-Myers Squibb. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
